Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Steris plc filings on SEC EDGAR ↗
Steris Sr. Vice Pres., CFO Karen L. Burton Sells $1.5M of Stock
Karen L. Burton, Sr. Vice Pres., CFO, sold 5,880 shares of Steris plc at $255.62 a share, worth $1.5M in total on Nov 11, 2026. Shares held after the trade: 12,956 (-31.2%).
Mohsen Sohi sold 4,893 shares of Steris plc at $252.87 to $253.90 a share (average $253.22) in 2 transactions, worth $1.24M in total on Nov 10, 2026. Shares held after the trade: 24,305 (-6.4%).
Steris $1.5B Debt Financing with J.P. Morgan Securities LLC
STERIS plc's subsidiary, STERIS Irish FinCo Unlimited Company, priced an offering of $1.5 billion in senior notes, consisting of $750 million due 2033 at 5.650% and $750 million due 2036 at 5.875%. The proceeds will be used to fund the pending acquisition of Xodus Medical, Inc., transaction expenses, and general corporate purposes.
STERIS plc reported total revenues of $1,588.6 million for the quarter ended September 30, 2026, an 8.8% increase compared to the prior year. Net income attributable to shareholders rose to $213.7 million, driven by growth in both product and service segments, while the company continued its share repurchase program with $215.9 million spent in the first six months of the fiscal year.
Steris $1.6B Debt Financing with JPMorgan Chase Bank, N.A.
STERIS plc entered into a new $1.6 billion revolving credit agreement with JPMorgan Chase Bank and other lenders, replacing its existing 2024 facility. The new facility matures on November 4, 2031, and includes an accordion feature allowing for an incremental increase of up to $800 million. The proceeds will be used for general corporate purposes, including swingline borrowings and letters of credit.
STERIS reported fiscal 2027 second quarter revenue of $1.6 billion, a 9% increase driven by strong performance in the Life Sciences segment. Adjusted EPS rose to $2.94, benefiting from approximately $20 million in tariff refunds. The company raised its full-year outlook based on solid underlying demand and segment performance.
Term
Q2 2027
“Life Sciences delivered particularly strong performance in the quarter, giving us confidence to raise our expectations for the segment for the full year. Our updated outlook reflects stable underlying performance, plus the benefit of tariff refunds received year-to-date. Fiscal 2027 is shaping up to be another record year for STERIS, supported by solid underlying demand and excellent execution from our commercial teams.”